Cancer stem cell based adjuvant for oncoantingen-driven vaccination
Authors: 
Francesca Cordero, Stefania Lanzardo, Maddalena Arigoni, Chiara Fornari, Laura Conti, Gianfranco Balbo, Federica Cavallo, Daniele Manini, Raffaele A. CalogeroAuthors Info & Claims
Francesca Cordero, Stefania Lanzardo, Maddalena Arigoni, Chiara Fornari, Laura Conti, Gianfranco Balbo, Federica Cavallo, Daniele Manini, Raffaele A. CalogeroAuthors Info & ClaimsPages 564 - 568
Abstract
The aim of this work is the identification of adjuvant molecules that can be associated to an oncoantigen-driven vaccination. By microarray analysis and data mining we have identified a set of drugs targeting genes that are associated to breast cancer stem cells (CSC): Atorvastatin, Bumetanide, Radafaxine, ICA 17043. YSL. In vitro characterization of one of these drugs, Atorvastatin. showed its ability to impair mammosphere formation, which is a peculiarity of normal and cancer stem cells. A mathematical model to simulate the effect of the combination of adjuvant and vaccination was designed and parameters defined on the basis of ErbB2-driven vaccination and Atorvastatin activity on CSC. The model suggests that reduction and halting of tumor mass increment can be reached by combining the effect of ErbB2 vaccination and 5 μM Atorvastatin as adjuvant.
References
[1]
{Lollini et al. 2006} Lolllini, P. L., Cavallo, F., Narnii, P. and Forni, G. 2006. Vaccines for tumour prevention. Nat Rev Cancer 6, 204--216.
[2]
Cavallo, F., De Giovanni, C., Nanni, P., Forni, G. and Lollini, P. L. 2011. 2011: the immune hallmarks of cancer. Cancer Immunol Immunother 60, 319--326.
[3]
Clarke, M. F. And Fuller, M. 2006. Stem cells and cancer: two faces of eve. Cell 124, 1111--1115.
[4]
Frank, N. Y., Schatton, T. And Frank, M. H. 2010. The therapeutic promise of the cancer stem cell concept. J Clin Invest 120, 41--50.
[5]
Kim, C. F., Jackson, E. L., Woolfenden, A. E., Lawrence, S., Babar, I., Vogel, S., Crowley, D., Bronson, R. T. And Jacks, T. 2005. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121, 823--835.
[6]
Rovero, S., Amici, A., Di Carlo, E., Bei, R., Nanni, P., Quaglino, E., Porcedda, P., Boggio, K., Smorlesi, A., Lollini, P. L., Landuzzi, L., Colombo, M. P., Giovarelli, M., Musiani, P. And Forni, G 2000. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 165, 5133--5142.
[7]
Grange, C., Lanzardo, S., Cavallo, F., Camussi, G And Bussolati, B. 2008. Sca-1 identifies the tumor-initiating cells in mammary tumors of BALB-neuT transgenic mice. Neoplasia 10, 1433--1443.
[8]
Cavallo, F., Calogero, RA. And Forni, G 2007. Are oncoantigens suitable targets for anti-tumour therapy? Nat Rev Cancer 7, 707--713.
[9]
Calogero, RA., Quaglino, E., Saviozzi, S., Forni, G. And Cavallo, F. 2008. Oncoantigens as anti-tumor vaccination targets: the chance of a lucky strike? Cancer Immunol Immunother 57, 1685--1694.
[10]
Van Wijk, B. L., Klungel, O. H., Heerdink, E. R. And De Boer, A. 2006. A comparison of two multiple-characteristic decision-making models for the comparison of antihypertensive drug classes: Simple Additive Weighting (SAW) and Technique for Order Preference by Similarity to an Ideal Solution (TOPSIS). Am J Cardiovasc Drugs 6, 251--258.
[11]
Sassano, A., Lo Iacono, M., Antico, G., Jordan, A., Uddin, S., Calogero, RA. AND Platanias, L. C. 2009. Regulation of leukemic cell differentiation and retinoid-induced gene expression by statins. Mol Cancer Ther 8, 615--625.
[12]
Frank, N. Y., Schatton, T. And Frank, M. H. 2010. The therapeutic promise of the cancer stem cell concept. J Clin Invest 120, 41--50.
[13]
Turner, C. And Kohandel, M. 2010. Investigating the link between epithelial-mesenchymal transition and the cancer stem cell phenotype: A mathematical approach. J Theor Biol 265, 329--335
[14]
Gupta, P. B., Chaffer, C. L. And Weinberg, R. A. 2009. Cancer stem cells: mirage or reality? Nat Med 15, 1010--1012
[15]
Zhu, X., Zhou, X., Lewis, M. T., Xia, L. And Wong, S. 2011. Cancer stem cell, niche and EGFR decide tumor development and treatment response: A bio-computational simulation study. J Theor Biol 269, 138--149.
Index Terms
- Cancer stem cell based adjuvant for oncoantingen-driven vaccination
Recommendations
Evolutionary Optimization of Cancer Treatments in a Cancer Stem Cell Context
GECCO '15: Proceedings of the 2015 Annual Conference on Genetic and Evolutionary ComputationWe used evolutionary computing for optimizing cancer treatments taking into account the presence and effects of cancer stem cells. We used a cellular automaton to model tumor growth at cellular level, based on the presence of the main cancer hallmarks ...
Cancer adjuvant chemotherapy strategic classification by artificial neural network with gene expression data
Display Omitted Adjuvant chemotherapy for non-small cell lung cancer (NSCLC) is still controversial.Prediction of adjuvant chemotherapy benefit in NSCLC using ANN with gene expression data.Using gene signature profiles to predict ACT benefit in NSCLC is ...
Regulation of Telomerase in Normal and Cancer Stem Cells
ICBRA '24: Proceedings of the 11th International Conference on Bioinformatics Research and ApplicationsDysfunction of telomerase, a ribonucleoprotein that repairs telomeres, can lead to cancer. Telomerase activity varies between different types of cells and is abnormally high in cancer stem cells due to changes in the regulation of telomerase, resulting ...
Comments
Information & Contributors
Information
Published In
August 2011
688 pages
ISBN:9781450307963
DOI:10.1145/2147805
- General Chairs:
- Robert Grossman,
- Andrey Rzhetsky,
- Program Chairs:
- Sun Kim,
- Wei Wang
Copyright © 2011 ACM.
Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for components of this work owned by others than ACM must be honored. Abstracting with credit is permitted. To copy otherwise, or republish, to post on servers or to redistribute to lists, requires prior specific permission and/or a fee. Request permissions from [email protected]
Sponsors
Publisher
Association for Computing Machinery
New York, NY, United States
Publication History
Published: 01 August 2011
Check for updates
Author Tags
Qualifiers
- Research-article
Conference
BCB' 11
Sponsor:
BCB' 11: ACM International Conference on Bioinformatics, Computational Biology and Biomedicine
August 1 - 3, 2011
Illinois, Chicago
Acceptance Rates
Overall Acceptance Rate 254 of 885 submissions, 29%
Contributors
Other Metrics
Bibliometrics & Citations
Bibliometrics
Article Metrics
- 0Total Citations
- 79Total Downloads
- Downloads (Last 12 months)2
- Downloads (Last 6 weeks)0
Reflects downloads up to 07 Mar 2025
Other Metrics
Citations
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Sign in